Literature DB >> 26276748

Noninvasive molecular screening for oral precancer in Fanconi anemia patients.

Stephanie E Smetsers1, Eunike Velleuer2, Ralf Dietrich3, Thijs Wu1, Arjen Brink1, Marijke Buijze1, Dorly J H Deeg4, Jean Soulier5, C René Leemans1, Boudewijn J M Braakhuis1, Ruud H Brakenhoff6.   

Abstract

LOH at chromosome arms 3p, 9p, 11q, and 17p are well-established oncogenetic aberrations in oral precancerous lesions and promising biomarkers to monitor the development of oral cancer. Noninvasive LOH screening of brushed oral cells is a preferable method for precancer detection in patients at increased risk for head and neck squamous cell carcinoma (HNSCC), such as patients with Fanconi anemia. We determined the prevalence of LOH in brushed samples of the oral epithelium of 141 patients with Fanconi anemia and 144 aged subjects, and studied the association between LOH and HNSCC. LOH was present in 14 (9.9%) nontransplanted patients with Fanconi anemia, whereas LOH was not detected in a low-risk group (n = 50, >58 years, nonsmoking/nonalcohol history) and a group with somewhat increased HNSCC risk (n = 94, >58 years, heavy smoking/excessive alcohol use); Fisher exact test, P = 0.023 and P = 0.001, respectively. Most frequent genetic alteration was LOH at 9p. Age was a significant predictor of LOH (OR, 1.13, P = 0.001). Five patients with Fanconi anemia developed HNSCC during the study at a median age of 39.6 years (range, 24.8-53.7). LOH was significantly associated with HNSCC (Fisher exact test, P = 0.000). Unexpectedly, the LOH assay could not be used for transplanted patients with Fanconi anemia because donor DNA in brushed oral epithelium, most likely from donor leukocytes present in the oral cavity, disturbed the analysis. Noninvasive screening using a LOH assay on brushed samples of the oral epithelium has a promising outlook in patients with Fanconi anemia. However, assays need to be adapted in case of stem cell transplantation, because of contaminating donor DNA. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26276748     DOI: 10.1158/1940-6207.CAPR-15-0220

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  5 in total

1.  Transforming Cancer Prevention through Precision Medicine and Immune-oncology.

Authors:  Thomas W Kensler; Avrum Spira; Judy E Garber; Eva Szabo; J Jack Lee; Zigang Dong; Andrew J Dannenberg; William N Hait; Elizabeth Blackburn; Nancy E Davidson; Margaret Foti; Scott M Lippman
Journal:  Cancer Prev Res (Phila)       Date:  2016-01

2.  Management of oral leukoplakia in patients with Fanconi anemia.

Authors:  Roberto Pippi; Cira Di Gioia; Ursula La Rocca; Amelia Bellisario; Anna Paola Iori
Journal:  J Oral Maxillofac Pathol       Date:  2022-02-28

3.  A New Multi-Color FISH Assay for Brush Biopsy-Based Detection of Chromosomal Aneuploidy in Oral (Pre)Cancer in Patients with Fanconi Anemia.

Authors:  Bruno Eduardo Silva de Araujo; Mona Markgraf; Isabela Karoline de Santana Almeida Araujo; Eunike Velleuer; Ralf Dietrich; Natalia Pomjanski; Martin Schramm
Journal:  Cancers (Basel)       Date:  2022-07-17       Impact factor: 6.575

4.  Risk Stratification of Oral Potentially Malignant Disorders in Fanconi Anemia Patients Using Autofluorescence Imaging and Cytology-On-A Chip Assay.

Authors:  Timothy J Abram; Curtis R Pickering; Alexander K Lang; Nancy E Bass; Rameez Raja; Cynthia Meena; Amin M Alousi; Jeffrey N Myers; John T McDevitt; Ann M Gillenwater; Nadarajah Vigneswaran
Journal:  Transl Oncol       Date:  2018-02-24       Impact factor: 4.243

5.  Chemopreventive targeted treatment of head and neck precancer by Wee1 inhibition.

Authors:  Anne M van Harten; D Vicky de Boer; Sanne R Martens-de Kemp; Marijke Buijze; Sonja H Ganzevles; Keith D Hunter; C René Leemans; Victor W van Beusechem; Rob M F Wolthuis; Renée X de Menezes; Ruud H Brakenhoff
Journal:  Sci Rep       Date:  2020-02-11       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.